Home › Core › ISCC-IDs › 28CrYY3UmidC9

View ISCC-ID

Core Data

28CrYY3UmidC9
ISCC-ID - digital asset identifier
CCd6Sn7UV14eT-CThy78WwH2XaL-CD8NhYL52B1jh-CRmQV8eykBkZm
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

pd4712 enzalutamide and pdl1 inhibitors exert antiproliferative effects on different signaling pathways in urothelial cancer

Ledger Reference

coblo
Source Ledger/Blockchain
12398232
N-th ISCC Decleration on source ledger
00cbebde9eefd2cf688d116719f7dd83bedae062e48abd85c1c8dfa42605dd25
Hash of block that includes the ISCC-DECLARATION
20243c073cb228fe7569ac9760336df30dda9054eba22d21e03891d08c619daf
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "PD47-12\u2003ENZALUTAMIDE AND PD-L1 INHIBITORS EXERT ANTI-PROLIFERATIVE EFFECTS ON DIFFERENT SIGNALING PATHWAYS IN UROTHELIAL CANCER", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Georgios Gakis*", "@type": "Person"}, {"name": "Tina Schubert", "@type": "Person"}, {"name": "Markus Krebs", "@type": "Person"}, {"name": "Hubert K\u00fcbler", "@type": "Person"}, {"name": "Elke Butt-D\u00f6rje", "@type": "Person"}, {"name": "Burkhard Kneitz", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://www.auajournals.org/doi/pdf/10.1097/01.JU.0000556768.46618.c3", "encodingFormat": "application/pdf"}], "publisher": {"name": "Ovid Technologies (Wolters Kluwer Health)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1097/01.ju.0000556768.46618.c3", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCd6Sn7UV14eT-CThy78WwH2XaL-CD8NhYL52B1jh-CRmQV8eykBkZm", "propertyID": "ISCC"}], "datePublished": "2019-04-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close